Provided by Tiger Trade Technology Pte. Ltd.

Oculis

25.37
-0.9300-3.54%
Post-market: 25.370.00000.00%17:51 EDT
Volume:473.51K
Turnover:12.04M
Market Cap:1.47B
PE:-10.65
High:26.36
Open:26.09
Low:24.98
Close:26.30
52wk High:30.68
52wk Low:14.00
Shares:57.81M
Float Shares:44.06M
Volume Ratio:1.75
T/O Rate:1.07%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.3818
EPS(LYR):-2.3426
ROE:-73.45%
ROA:-28.65%
PB:5.91
PE(LYR):-10.83

Loading ...

Oculis to Spotlight Transformative Late-Stage Pipeline at Eyecelerator and AAO 2025

GlobeNewswire
·
Oct 14, 2025

Oculis to Spotlight Transformative Late-Stage Pipeline at Eyecelerator and AAO 2025

GlobeNewswire
·
Oct 14, 2025

Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities

GlobeNewswire
·
Oct 09, 2025

2 Outstanding Healthcare Stocks to Buy and Hold for a Decade

Motley Fool
·
Oct 08, 2025

Chardan Research Adjusts Oculis Holding AG Price Target to $51 From $33, Maintains Buy Rating

MT Newswires Live
·
Oct 08, 2025

Oculis Holding Is Maintained at Buy by Chardan Capital

Dow Jones
·
Oct 08, 2025

Chardan Capital Reaffirms Their Buy Rating on Oculis Holding (OCS)

TIPRANKS
·
Oct 08, 2025

Oculis price target raised to $30 from $28 at BofA

TIPRANKS
·
Oct 07, 2025

Oculis Holding Ag : Bofa Global Research Raises Price Objective to $30 From $28

THOMSON REUTERS
·
Oct 07, 2025

Oculis Holding Is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
Oct 07, 2025

Oculis price target raised to $36 from $33 at H.C. Wainwright

TIPRANKS
·
Oct 07, 2025

Oculis Advances Privosegtor into Registrational Trials for Neuro-Ophthalmology

TIPRANKS
·
Oct 07, 2025

Oculis Holding (OCS) Gets a Buy from Bank of America Securities

TIPRANKS
·
Oct 07, 2025

Oculis Accelerates Privosegtor into Registrational Trials in Acute Optic Neuritis, Pioneering the Path for a Potential First-in-class Neuroprotective Therapy

GlobeNewswire
·
Oct 06, 2025

Oculis Publishes Notification of Transactions by Person Discharging Managerial Responsibilities

GlobeNewswire
·
Sep 27, 2025

AI Drives Surge! OCS Concept Stocks Collectively Soar While Shareholders Quietly Reduce Holdings

Deep News
·
Sep 22, 2025

Oculis Announces Presentation of Phase 2 ACUITY trial results with Privosegtor in Acute Optic Neuritis at ECTRIMS

GlobeNewswire
·
Sep 22, 2025